Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 802 across all filing types
Latest filing 2010-07-21 Interim / Quarterly Rep…
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2010
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half of the year 2010 (HY1). It contains detailed financial statements, including the statement of financial position, statement of income, and statement of cash flows, along with extensive management analysis of the financial results. It is not merely an announcement of a report, as it provides the actual financial data and tables. Therefore, it fits the definition of an Interim/Quarterly Report. H1 2010
2010-07-21 English
Pharming completes spin-off of DNage
M&A Activity Classification · 99% confidence The document is a press release dated July 19, 2010, announcing that the spin-off of the subsidiary DNage by Pharming Group NV has become definitive. This announcement details a change in corporate structure, specifically a divestment/spin-off where Pharming retains a 51% interest and settles earn-out payments via shares and a minority stake. This action directly relates to changes in the company's capital structure and corporate organization, fitting best under 'Capital/Financing Update' (CAP) as it involves share transfers, settlement of obligations via shares, and a change in subsidiary ownership structure. While it is an announcement, it is a specific corporate action announcement rather than a general 'Report Publication Announcement' (RPA) or a generic 'Regulatory Filing' (RNS).
2010-07-19 English
Pharming provides update on outstanding shares
Share Issue/Capital Change Classification · 99% confidence The document is a press release from Pharming Group NV dated July 12, 2010, titled 'PHARMING PROVIDES UPDATE ON OUTSTANDING SHARES'. It explicitly details an increase in the number of outstanding shares due to warrant exercises, bond conversions, and interest payments. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition of 'Share Issue/Capital Change' (Code: SHA), which covers announcements regarding new share issues or capital changes.
2010-07-12 English
Pharming and Sanofi Chimie sign manufacturing agreement for the drug substance of Ruconest
Regulatory Filings Classification · 95% confidence The document is a press release dated July 6th, 2010, announcing the signing of a manufacturing agreement between Pharming and Sanofi Chimie for the drug substance of Ruconest™. It details business developments, strategic partnerships, and regulatory milestones (like the positive opinion from CHMP). This type of announcement, focusing on a significant business transaction or operational update that is not a formal financial filing (like 10-K or IR) or a standard earnings release (ER), fits best under the general category of Regulatory Filings (RNS) or potentially a specific business update if one were available. Since it is a general announcement of a material event that doesn't fit the other specific codes (like M&A, CAP, or ER), RNS is the most appropriate fallback for a non-standard regulatory announcement/press release. The length (4349 chars) is substantial enough that it is not just a brief 'Report Publication Announcement' (RPA).
2010-07-06 English
Pharming provides update on outstanding shares
Share Issue/Capital Change Classification · 99% confidence The document is a press release titled "PHARMING PROVIDES UPDATE ON OUTSTANDING SHARES". It explicitly details changes in the number of outstanding shares, attributing the increase to bond conversions and warrant exercises. This directly relates to changes in the company's capital structure. Based on the definitions, the most appropriate category is 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital structure changes. It is not an Earnings Release (ER) or a general Regulatory Filing (RNS) because it fits a specific category.
2010-06-30 English
Pharming receives positive opinion from European Medicines Agency on Rhucin
Earnings Release Classification · 95% confidence The document is a press release dated June 24, 2010, announcing that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the product Ruconest (formerly Rhucin) for HAE treatment. It details regulatory steps, commercialization plans, and includes a section for a conference call. This format—a formal announcement of a significant business/regulatory event, often including financial context and forward-looking statements, but not being a full periodic report (like 10-K or IR) or a transcript—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on a major regulatory milestone (positive opinion leading to expected Marketing Authorization) and includes details about the product and market, it functions as an initial announcement of significant news. Given the options, 'Earnings Release' (ER) is often used for major operational/regulatory news releases, although 'Regulatory Filings' (RNS) is also plausible. However, the content is a direct announcement of a key business development, which aligns closely with the function of an ER, even if it's not strictly quarterly earnings. Since it is a formal press release announcing a major regulatory event and commercial progress, and it is not a transcript, a formal report, or a proxy statement, ER is the most fitting category for a significant, time-sensitive announcement. Q2 2010
2010-06-24 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.